[CAS NO. 603-50-9] Bisacodyl

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [603-50-9]

Catalog

AS988033

Brand

Arctom Scientific

CAS

603-50-9

DESCRIPTION [603-50-9]

Overview

MDL	-
Molecular Weight	361.39
Molecular Formula	C22H19NO4
SMILES	CC(OC1=CC=C(C(C2=CC=C(OC(C)=O)C=C2)C3=NC=CC=C3)C=C1)=O

For research use only. We do not sell to patients.

Summary

Bisacodyl is a stimulant laxative agent that works directly on the colon to produce a bowel movement. Bisacodyl increases the secretion of PGE ₂ by direct activation of colon macrophages. PGE ₂ acts as a paracrine factor and decreases the expression of AQP3 in the colon, which inhibits water transfer from the luminal to the vascular side and leads to a laxative effect ^[1] .

In Vivo

Bisacodyl (20 mg/kg) results in a decrease in AQP3 protein expression and increased mRNA expression level of TNF-α in the colon of rats [1]. Bisacodyl inhibits water absorption in rat jejunum, ileum, and colon, the degree of inhibition is linearly related to the logarithm of the bisacodyl concentration over the range of 0.05 mg to 2.0 mg per 100 mL [2]. Bisacodyl (10 mg/kg, intragastrically) induces a significant decrease in jejunal NOS activity in rats. Bisacodyl (10 mg/kg, intragastrically) increases the distance traveled by the marker in all time periods [3]. Bisacodyl (5.9 mg/kg) decreases significantly jejunal and colonic (Na + K) ATPase activity as compared to saline-treated rats. Bisacodyl (5.9 mg/kg) increases significantly jejunal and colonic PGE2 content and stimulates jejunal and colonic adenyl cyclase activity as compared to those in control rats without affecting cAMP content [4]. Bisacodyl (4.3 mg/kg) coupled with AOM increases the number of crypt per focus, but not the number of tumors in rats. Bisacodyl (43 mg/kg) significantly increases the number of crypt per focus and tumors in rats [5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04930237	Methodist Health System	OIC	July 1, 2021
NCT01745835	Seoul National University Hospital	Healthy Person\|Bowel Preparation Before Colonoscopy	January 30, 2013	Phase 3
NCT02386449	Ferring Pharmaceuticals	Bowel Preparation	February 2015	Phase 4
NCT01865916	University of British Columbia	Colonoscopy	April 2013	Phase 4
NCT02383758	Emory University\|Organization for Autism Research	Encopresis\|Autistic Disorder	February 1, 2015	Not Applicable
NCT01073943	Ferring Pharmaceuticals	Bowel Preparation	May 2010	Phase 3
NCT05032794	Hospital Parc Taulí, Sabadell	Bowel Cleansing\|Colonoscopy\|Bowel Cancer	October 13, 2021	Not Applicable
NCT01853709	Corporacion Parc Tauli	Bowel Preparation for Colonoscopy	May 2013	Phase 4
NCT01685853	European Institute of Oncology	Colonoscopy	April 2011	Phase 3
NCT01655095	Queen´s University\|Hotel Dieu Hospital (Gastrointestinal Diseases Research Unit)	Quality of Bowel Preparation for the Colon Capsule\|Colon Capsule Completion Rates\|Colon Capsule Polyp Detection	July 2012	Phase 3
NCT02481219	Medtronic - MITG	Colorectal Cancer Screening	May 2015	Not Applicable
NCT04033250	Rambam Health Care Campus	Inadequate Preparation for Colonoscopy; Personalized Colonoscopy Preparation	September 2019	Not Applicable
NCT04132661	University of Nottingham\|Sanofi	Constipation	September 25, 2020	Phase 4
NCT01063049	Gastroenterology Services, Ltd.	Preparation for Colonoscopy	February 2010	Phase 4
NCT02415569	Shandong University\|Qianfoshan Hospital\|Binzhou People´s Hospital	Bowel Cleansing Quality	January 2015	Phase 4
NCT02609607	David Levinthal\|Consortium of Multiple Sclerosis Centers\|University of Pittsburgh	Constipation\|Fecal Incontinence\|Multiple Sclerosis	June 2016	Phase 2
NCT01011426	The Cooper Health System	Postoperative Nausea and Vomiting\|Abdominal Pain	April 2009	Phase 2
NCT02211911	Boehringer Ingelheim	Healthy	February 2008	Phase 1
NCT03279341	University Hospital, Gasthuisberg	Chronic Constipation	December 3, 2012	Phase 4
NCT00857272	Braintree Laboratories	Colonoscopy	February 2009	Phase 4
NCT02040285	Azienda Policlinico Umberto I	Gastrointestinal Complication	February 2012	Phase 4
NCT02211976	Boehringer Ingelheim	Constipation	October 2003	Phase 3
NCT02119000	McGill University Health Centre+Research Institute of the McGill University Health Centre	Hospitalized Patients	August 2015	Phase 4
NCT00953017	Brooke Army Medical Center	Colonoscopy	July 2009	Phase 4
NCT00509327	University Hospital, Basel, Switzerland	Postoperative Ileus	November 2004	Phase 4
NCT03226145	University of Nottingham\|University College, London\|Queen Mary University of London	Constipation - Functional\|Irritable Bowel Syndrome Characterized by Constipation	July 20, 2017	Not Applicable
NCT03146052	ASST Rhodense	Polyps\|Colon Preparation	March 27, 2017	Not Applicable
NCT05144295	Alexandria University	Clinical Efficacy\|Treatment Efficacy\|Drug Side Effect	January 1, 2022	Phase 3
NCT03248726	Taipei Medical University WanFang Hospital	Bowel Preparation	July 14, 2017	Not Applicable
NCT02980562	Korea University Anam Hospital	Bowel Disease\|Colon Adenoma	May 2015	Phase 3
NCT01887158	Ospedale Santa Maria delle Croci	Intestinal Cancer	July 2013	Phase 4
NCT04903470	University of California, San Diego	Constipation by Outlet Obstruction	June 15, 2021	Not Applicable
NCT01982240	Bausch Health Americas, Inc.	Chronic Idiopathic Constipation	November 2013	Phase 3
NCT01415687	University of Calgary	Bowel Preparation for Colonoscopy	May 2011	Phase 3
NCT01627171	St. Joseph´s Healthcare Hamilton\|McMaster University	Endoscopy\|Bowel Preparation Solutions	September 2012	Phase 4
NCT02976805	Lawson Health Research Institute\|Academic Medical Organization of Southwestern Ontario\|Pendopharm\|University of Alberta\|Université de Montréal\|McGill University\|University of Western Ontario, Canada	Colonoscopy\|Bowel Preparation	February 13, 2017	Phase 3
NCT04129788	University of Nottingham\|Sanofi	Constipation	November 4, 2020	Phase 4
NCT00410215	Queen´s University	Colonoscopy	February 2006	Phase 4
NCT01885104	Bayer	Constipation	April 2013	Phase 2
NCT01509131	Promefarm S.r.l.	Colonoscopy	March 2010	Phase 4
NCT00526097	Boehringer Ingelheim	Constipation	September 2007	Phase 3
NCT00425594	Braintree Laboratories	Colonoscopy	January 2007	Phase 4
NCT00779649	Research Associates of New York, LLP	Colonoscopy	September 2008	Phase 4
NCT01533090	Catholic University of the Sacred Heart	Colonic Polyps\|Cancer Colon\|Inflammatory Bowel Disease	April 2010	Not Applicable
NCT00278967	Braintree Laboratories	Colonoscopy	February 2006	Phase 4
NCT01073930	Ferring Pharmaceuticals	Bowel Preparation	May 2010	Phase 3
NCT01533688	University of Oklahoma	Diabetes Mellitus	October 2011	Not Applicable
NCT02977286	Tufts Medical Center	Constipation	January 1, 2017	Phase 4
NCT01917773	Indiana University	Colonic Motility Index\|Constipation	August 2013	Phase 4
NCT01879605	Oslo University Hospital	Constipation\|Ileus\|Surgery	December 2007	Phase 4
NCT03849196	Samsung Medical Center	Bowel Preparation	July 31, 2017	Not Applicable
NCT01044394	Boston Medical Center	Bowel Preparation	January 2010	Phase 2
NCT05409157	Bristol-Myers Squibb	Healthy Participants	June 17, 2022	Phase 1
NCT01510977	Asan Medical Center	Colonoscopy Failure\|Poor Bowel Preparation	November 2011	Phase 4

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 138.35 mM ; Need ultrasonic)

H ₂ O : 0.1 mg/mL ( 0.28 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7671 mL	13.8355 mL	27.6709 mL
5 mM	0.5534 mL	2.7671 mL	5.5342 mL
10 mM	0.2767 mL	1.3835 mL	2.7671 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (6.92 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (6.92 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (6.92 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Phenol, 4,4′-(2-pyridinylmethylene)bis-, 1,1′-diacetate

Phenol, 4,4′-(2-pyridylmethylene)di-, diacetate (ester)

Phenol, 4,4′-(2-pyridinylmethylene)bis-, diacetate (ester)

Phenol, 4,4′-(2-pyridylmethylene)di-, diacetate

Bis(p-acetoxyphenyl)-2-pyridylmethane

Bisacodyl

Dulcolan

Dulcolax

LA96a

Laxans

4,4′-(2-Pyridylmethylene)diphenol diacetate

Pyrilax

Brocalax

Telemin

Nigalax

Laco

Laxadin

Laxorex

Durolax

Perilax

Hillcolax

Ivilax

Sanvacual

Neolax

Videx

Zetrax

Laxine

Fenilaxan

Bicol

Theralax

Godalax

Endokolat

Correctol Caplets

Broxalax

Laxanin N

Contralax

Stadalax

Ulcol

Correctol Tablets

Feen-a-Mint Tablets

SK-Bisacodyl

DAMP

Eulaxan

NSC 614826

Prepacol

Fleet

Alophen

(Pyridin-2-ylmethylene)bis(4,1-phenylene) diacetate